Intrahepatic metastases may be specific to hepatocellular carcinoma due to the coagulation and fibrinolytic systems (Review)

Oncol Rep. 2020 Dec;44(6):2345-2352. doi: 10.3892/or.2020.7800. Epub 2020 Oct 9.

Abstract

Hepatocellular carcinoma (HCC) is different from other solid tumors because it is commonly associated with the occurrence of intrahepatic metastasis. Additionally, the liver, unlike other organs, is the main site of coagulation and fibrinolytic factor production. Therefore, it was speculated that coagulation and fibrinolytic factors could be associated with intrahepatic metastasis of HCC. Do the coagulation and fibrinolytic systems protect HCC cells against anoikis during infiltration and metastasis? Conversely, do the coagulation and fibrinolytic systems lead to immune escape of HCC cells by affecting the immune microenvironment of patients? The current review aimed to present a number of novel hypotheses for the treatment of HCC by exploring the mechanisms of coagulation and fibrinolytic factors in the regulation of cancer growth.

Keywords: hepatocellular carcinoma; intrahepatic metastasis; coagulation-fibrinolytic system; anti-anoikis; immune escape.

Publication types

  • Review

MeSH terms

  • Anoikis / drug effects
  • Anoikis / immunology
  • Biomarkers / metabolism
  • Blood Coagulation / drug effects
  • Blood Coagulation / immunology*
  • Carcinogenesis / drug effects
  • Carcinogenesis / immunology
  • Carcinogenesis / pathology
  • Carcinoma, Hepatocellular / blood
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / immunology
  • Carcinoma, Hepatocellular / secondary*
  • Humans
  • Liver / immunology
  • Liver / pathology*
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / immunology
  • Liver Neoplasms / pathology*
  • Liver Neoplasms / secondary*
  • Protease Inhibitors / pharmacology
  • Protease Inhibitors / therapeutic use
  • Protein Precursors / metabolism
  • Prothrombin / metabolism
  • Tumor Escape / drug effects
  • Tumor Microenvironment / drug effects
  • Tumor Microenvironment / immunology
  • Urokinase-Type Plasminogen Activator / antagonists & inhibitors
  • Urokinase-Type Plasminogen Activator / metabolism

Substances

  • Biomarkers
  • Protease Inhibitors
  • Protein Precursors
  • acarboxyprothrombin
  • Prothrombin
  • Urokinase-Type Plasminogen Activator